company background image
MRSN

Mersana Therapeutics NasdaqGS:MRSN Stock Report

Last Price

US$6.89

Market Cap

US$687.4m

7D

3.3%

1Y

61.4%

Updated

03 Feb, 2023

Data

Company Financials +

Mersana Therapeutics, Inc.

NasdaqGS:MRSN Stock Report

Mkt Cap: US$687.4m

MRSN Stock Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.

MRSN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Mersana Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mersana Therapeutics
Historical stock prices
Current Share PriceUS$6.89
52 Week HighUS$8.34
52 Week LowUS$2.68
Beta1.72
1 Month Change27.36%
3 Month Change-8.62%
1 Year Change61.36%
3 Year Change4.55%
5 Year Change-49.19%
Change since IPO-50.79%

Recent News & Updates

Recent updates

Mersana gains as FDA grants fast track status for breast cancer drug

Sep 12

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Aug 15

Taking The Measure Of Mersana Therapeutics

Jan 10

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

Jun 29

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Jun 05
It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Mersana Therapeutics EPS misses by $0.11, misses on revenue

May 10

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mar 23
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Jan 29
Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Bain Capital discloses 4.8% stake in Mersana Therapeutics

Jan 13

Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst

Jan 11

Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study

Jan 05

Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?

Dec 08
Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?

Mersana Therapeutics EPS misses by $0.02

Nov 09

Shareholder Returns

MRSNUS BiotechsUS Market
7D3.3%-0.8%2.9%
1Y61.4%4.5%-8.5%

Return vs Industry: MRSN exceeded the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: MRSN exceeded the US Market which returned -9.1% over the past year.

Price Volatility

Is MRSN's price volatile compared to industry and market?
MRSN volatility
MRSN Average Weekly Movement9.9%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: MRSN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MRSN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001169Anna Protopapashttps://www.mersana.com

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate.

Mersana Therapeutics, Inc. Fundamentals Summary

How do Mersana Therapeutics's earnings and revenue compare to its market cap?
MRSN fundamental statistics
Market CapUS$687.44m
Earnings (TTM)-US$208.27m
Revenue (TTM)US$11.90m

57.7x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRSN income statement (TTM)
RevenueUS$11.90m
Cost of RevenueUS$165.04m
Gross Profit-US$153.14m
Other ExpensesUS$55.13m
Earnings-US$208.27m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.09
Gross Margin-1,286.46%
Net Profit Margin-1,749.59%
Debt/Equity Ratio27.5%

How did MRSN perform over the long term?

See historical performance and comparison